Yoshihisa Matsumoto

Yoshihisa Matsumoto

Auto-generated profile, based on publicly available information

Yoshihisa Matsumoto

Department of Palliative Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
KAKoji Amano
Koji Amano
IMIsseki Maeda
Isseki Maeda
HIHiroto Ishiki
Hiroto Ishiki
TMTomofumi Miura
Tomofumi Miura
YHYutaka Hatano
Yutaka Hatano
EIEast-Asian collaborative cross-cultural Study to Elucidate the Dying process (EASED) Investigators
East-Asian collaborative cross-cultural Study to Elucidate the Dying process (EASED) Investigators

1 October 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
HMHiromichi Matsuoka
Hiromichi Matsuoka
SISatoru Iwase
Satoru Iwase
TMTempei Miyaji
Tempei Miyaji
TKTakashi Kawaguchi
Takashi Kawaguchi
KAKeisuke Ariyoshi
Keisuke Ariyoshi
TYTakuhiro Yamaguchi
Takuhiro Yamaguchi
Although opioids and pregabalin are widely used for cancer-related neuropathic pain (CNP), no clinical trials exist to determine which medications are effective when an opioid-pregabalin combination therapy fails. We investigated the efficacy of duloxetine for CNP nonresponsive or intolerant to opioid-pregabalin combination therapy. A multicenter, randomized, double-blind, placebo-controlled trial was performed at 12 specialized palliative care services in Japan. Patients with CNP average pain scores (Brief Pain Inventory [BPI]-Item 5) ≥ 4 in the previous 24 hours and nonresponsive or intolerant to opioid-pregabalin combination therapy were eligible. Patients with chemotherapy-induced peripheral neuropathies were excluded. Patients were administered duloxetine 20 mg/day titrated to 40 mg/day or placebo for 10 days. The primary endpoint was BPI-Item 5 on Day 10. Responder analysis measured proportions of patients with 30% and 50% pain decreases. Seventy patients were enrolled. Complete case analysis revealed mean BPI-Item 5 on Day 10 of 4.03 for Group D vs. 4.88 for Group P (P = 0.053). Baseline observation carried forward analysis revealed mean BPI-Item 5 on Day 10 of 4.06 and 4.91 for Groups D and P, respectively (P = 0.048). Clinically meaningful pain improvement (≥30%) was reported by 44.1% (n = 15) of patients in Group D vs. 18.2% (n = 6) in Group P (P = 0.02); 32.4% (n = 11) vs. 3.0% (n = 1) of patients in Groups D and P, respectively, reported pain reduction ≥ 50% (P = 0.002). Adding duloxetine to opioid-pregabalin therapy might have clinical benefit in alleviating refractory CNP. Further studies are needed to conclude the efficacy of adding duloxetine.


1 December 2018 in European Journal of Cancer
Verified
Journal Article
Open access
JHJun Hamano
Jun Hamano
ATAyano Takeuchi
Ayano Takeuchi
TYTakuhiro Yamaguchi
Takuhiro Yamaguchi
MBMika Baba
Mika Baba
KIKengo Imai
Kengo Imai
TMTatsuya Morita
Tatsuya Morita
There have been no reports about predicting survival of patients with advanced cancer constructed entirely with objective variables. We aimed to develop a prognostic model based on laboratory findings and vital signs using a fractional polynomial (FP) model. A multicentre prospective cohort study was conducted at 58 specialist palliative care services in Japan from September 2012 to April 2014. Eligible patients were older than 20 years and had advanced cancer. We developed models for predicting 7-day, 14-day, 30-day, 56-day and 90-day survival by using the FP modelling method. Data from 1039 patients were analysed to develop each prognostic model (Objective Prognostic Index for advanced cancer [OPI-AC]). All models included the heart rate, urea and albumin, while some models included the respiratory rate, creatinine, C-reactive protein, lymphocyte count, neutrophil count, total bilirubin, lactate dehydrogenase and platelet/lymphocyte ratio. The area under the curve was 0.77, 0.81, 0.90, 0.90 and 0.92 for the 7-day, 14-day, 30-day, 56-day and 90-day model, respectively. The accuracy of the OPI-AC predicting 30-day, 56-day and 90-day survival was significantly higher than that of the Palliative Prognostic Score or the Prognosis in Palliative Care Study model, which are based on a combination of symptoms and physician estimation. We developed highly accurate prognostic indexes for predicting the survival of patients with advanced cancer from objective variables alone, which may be useful for end-of-life management. The FP modelling method could be promising for developing other prognostic models in future research.